ICS 2006 Scientific Podium Poster Session S11 - Clinical Pharmacology:Main Auditorium

Clinical Pharmacology:Main Auditorium

Scientific Podium Poster Session S11

	Thursday 30th November 2006
	15:00 - 16:30

Session Schedule

15:00

#83 Muscarinic receptors subtypes M2 and M3 in human urinary bladder disorders and their clinical correlations

Underwood J1, Mukerji G1, Yiangou Y2, Grogono J1, Agarwal S3, Khullar V1, Anand P2 1. St Marys Hospital, 2. Imperial College, 3. Hammersmith Hospital

15:07

#84 Quality of Life Following Treatment With Transdermal Oxybutynin: The Effects of Prior Therapy

Staskin D R1, Nitti V W2, Dmochowski R R3 1. -Cornell Medical School, New York Presbyterian Hospital, New York, NY, 2. , New York University School of Medicine, 3. Vanderbilt University School of Medicine

15:15

#85 Seasonal differences in patterns of improvement in urinary symptoms for Japanese OAB patients treated by the oxbutynin

Koyama N1, Homma Y2, Kawabe K3 1. Sankyo Company, LTD., 2. Japan Red Cross Medical Center, 3. Tokyo Teishin Hospital

15:22

#86 Patient-reported reasons for discontinuing overactive bladder (OAB) medications

Brubaker L1, Nichol M2, Fanning K3, Becker R4, Jumadilova Z5, Benner J4 1. Loyola University Medical Center, 2. University of Southern California, 3. Vedanta Research, 4. ValueMedics Research, LLC, 5. Pfizer, Inc

15:30

#87 DIFFERENTIAL EFFECTS OF THE ANTIMUSCARINIC AGENTS TOLTERODINE TARTRATE ER AND OXYBUTYNIN CHLORIDE ER ON RECENT MEMORY IN OLDER SUBJECTS

Kay G1, Kardiasmenos K2, Crook T3 1. Georgetown University School of Medicine, 2. Washington Neuropsychological Institute, 3. Cognitive Research Corporation

15:37

#88 EFFICACY OF TOLTERODINE VARIES IN RELATION TO DIFFERENT URODYNAMIC FINDINGS OF DETRUSOR OVERACTIVITY

Salvatore S1, Serati M1, Digesù A2, Triacca P3, Zanfrà M1, Bolis P1 1. Clinica ostetrica e Ginecologica, Università dell'Insubria, 2. Ospedale Bassini, Italy, 3. Ospedale La Spezia, Italy

15:45

#89 Comparison of solifenacin 5 mg and tolterodine ER 4 mg in the STAR OAB study

Chapple C1, Everaert K2, Lopatkin N3, Katona F4, Melekos M5, Madsen H6, Wright M7, Bolodeoku J7 1. Royal Hallamshire Hospital, Sheffield, UK, 2. Ghent University Hospital, Ghent, Belgium, 3. Moscow Institute of Urology, Moscow, Russia, 4. Josa Andras County Hospital, Nyiregyhaza, Hungary, 5. University of Thessalia, Larissa, Greece, 6. Aalborg Sygehus Nord, Aalborg, Denmark, 7. Astellas Pharma Europe, Staines, UK

15:52

#90 Antidiuresis in the treatment of overactive bladder syndrome

Hashim H1, Malmberg L2, Graugaard-Jensen C3, Abrams P1 1. Bristol Urological Institute, 2. Lund University Hospital , 3. University Hospital of Aarhus

16:00

#91 A Pilot Study to Assess the Effect of Treatment with an NK-1 Receptor Antagonist on Urge Urinary Incontinence Symptoms

Green S1, Bergner D2, Kaufman J3, Alon A1, Ianus J1, McNaughton K1, Tozzi C1, Reiss T1 1. Merck Research Labs, Merck & Co., Inc., 2. Tampa Bay Medical Research, Clearwater, FL, 3. Urology Research Options, Aurora, CO

16:07

#92 Nicorandil, a KATP channel opener and nitric oxide donor, was effective in the treatment of urinary frequency – a randomized clinical trial

Kamiyama Y1, Muto S1, Nishio K1, Saito K1, Yoshii T1, Ashizawa Y1, Kurihara K1, Isotani S1, Maruyama O1, Ide H1, Okada H1, Horie S1 1. Department of Urology, Teikyo University Hospital

16:15

#93 A Randomised Double-Blind Placebo Controlled Study to evaluate the Efficacy of Tamsulosin OCAS in the Management of Women with Overactive Bladder.

Robinson D1, Cardozo L1, Terpstra G 2, Bolodeoku J2 1. Dept of Urogynaecology, Kings College Hospital, 2. Astellas Pharma Europe BV

16:22

#94 Randomised Controlled Trial of Cannabis Based Medicine (CBM, Sativex®) to treat Detrusor Overactivity in Multiple Sclerosisdetect a difference

Kavia R1, De Ridder D2, Sarantis N3, Constantinescu C4, Fowler C J1 1. National Hospital for Neurology and Neurosurgery, 2. University Hospitals KU Leuven, 3. GW Pharmaceuticals, 4. Queen's Medical Centre, University of Nottingham